1. ALLA AKTIER
  2. NYHETER
  3. PROLIGHT DIAGNOSTICS

Prolight Diagnostics

Nyheter Prolight Diagnostics Nyheter alla bolag

Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share

Read the full article here: https://www.emergers.se/prolight_e/

For further information, please contact:
Ulf Bladin, CEO
E-mail: ub@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share

Datum 2024-08-30, kl 13:48
Källa MFN
Bifogade filer
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet